TLR9 and rheumatoid arthritis: As TLR9 is suggested to drive inflammation in NASH, anti-TLR9 mAb may be promising for therapeutic intervention in NASH or other diseases such as psoriasis, rheumatoid arthritis, and type 1 diabetes (Table 1) [47, 67–69].